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Abstract.  VLA-2 (also called gpla/IIa  on platelets)  is 
a  collagen  receptor with a  unique  ot subunit and a 
subunit common to other adhesion  receptors  in the 
VLA/integrin  family.  Multiple cDNA clones for the 
human  VLA-2 o~  2 subunit have been selected from a 
hgtll  library by specific antibody  screening.  The 5,374- 
bp nucleotide  sequence encoded for  1,181 amino acids, 
including  a  signal peptide of 29 amino acids followed 
by a  long extracellular  domain  (1,103 amino acids),  a 
transmembrane  domain,  and a  short cytoplasmic seg- 
ment  (22 amino acids).  Direct sequencing  of purified 
ot  z protein  confirmed the identity of the  15  NH2- 
terminal  amino acids.  Overall,  the ot  2 amino acid se- 
quence was  18-25%  similar  to the sequences known 
for other integrin  ot subunits.  In particular,  the a2 se- 
quence matched other integrin  c~ chains  in (a) the po- 
sitions of 17 of its 20 cysteine residues;  (b) the pres- 
ence of three  metal-binding  domains of the general 
structure  DXDXDGXXD;  and  (c) the transmembrane 
domain  sequence.  In addition,  the ot  2 sequence has a 
191-amino  acid insert  (called the 1-domain),  previ- 
ously found only in leukocyte integrins  of the 82 inte- 
grin  family.  The oe  2 I-domain  was 23-41%  similar  to 
domains  in cartilage  matrix protein and von 
Willebrand  factor,  which are perhaps  associated with 
collagen binding.  The NH2-terminal  sequence reported 
here  for c~  2 does not match the previously reported  o~  2 
NH2-terminal  sequence (Takada,  Y., J.  L.  Strominger, 
and M.  E.  Hemler.  1987. Proc. Natl.  Acad. Sci. USA. 
84:3239-3243).  Resolution of this discrepancy  sug- 
gests that there may be another  VLA heterodimer that 
resembles VLA-2 in size but has a different amino 
acid sequence. 
V 
LA-2  is an c~/~/-subunit cell surface heterodimer strong- 
ly implicated  as  receptor for collagen because (a) 
VLA-2  has  been  shown  to  be  identical  (61)  to  a 
150,000/ll0,000-Mr structure recognized by the mAb P1H5, 
which specifically blocks human fibrosarcoma cell (66) and 
platelet (31) attachment to collagen; (b) patients deficient in 
platelet protein Ia (or subunit of VLA-2) also lacked respon- 
siveness to collagen (27, 41); and (c) the mAb 12F1 was used 
to  identify  VLA-2  as  a  160,000/130,000-Mr  (nonreduced) 
platelet protein complex that mediates Mg2+-dependent ad- 
hesion to collagen (51, 52). Also in this regard, antigens that 
strongly resemble VLA-2 in size have been implicated in he- 
patocyte cell attachment  to type I collagen (14). 
The cell surface heterodimer VLA-2 was initially charac- 
terized as a "very late antigen" appearing on activated T cells 
(19, 20).  Later the mAb  12F1 was used to identify VLA-2 
on platelets and on many other cell types, including  most 
rapidly growing, adherent cell lines (43). Major portions of 
the platelet gpla and IIa are probably the same as the VLA-2 
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c~ and/3 subunits, respectively (31, 44). Thus the new plate- 
let-specific alloantigens  Br  ~ and  Br  b,  which  reside on the 
platelet Ia-IIa complex (53),  may be variable epitopes on 
VLA-2. 
In other studies, an antibody (called 5E8) that recognizes 
VLA-2 (Hemler,  M., and C.  Crouse,  unpublished  results) 
has  been described on most primary  human  lung  tumors 
(68), and ~25I-coupled 5E8 antibody has been used to inhibit 
the growth of lung tumor cell lines in vitro (57). 
The expression of VLA-2 can be up regulated on lympho- 
cytes in response to mitogen or antigen stimulation (17) and 
on fibroblasts in response to serum (10). Conversely, VLA-2 
expression slowly diminished when those stimuli were with- 
drawn and/or cells became quiescent (10, 17). Also, VLA-2 
expression can be up regulated by TGF/~ (15). 
Like other cell surface receptors for extracellular matrix 
components, VLA-2 belongs to the integrin superfamily (26, 
49).  Three subfamilies of that superfamily that are defined 
for humans are (a) the six (or more) VLA proteins (16, 23); 
(b) the  leukocyte adhesion  molecules,  LFA-1,  Mac-l,  and 
p150,95  (56);  and (c) the cytoadhesins,  which include the 
vitronectin receptor and platelet gplIb/IIIa (13). Within each 
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unique ot subunit associated with a common 13 subunit. Anal- 
yses of human eDNA clones for the/3 subunits of each sub- 
family  (called  13,  135, and/33,  respectively) have revealed 
that they are 44-47% similar (2, 12, 28, 33, 62), suggesting 
a common evolutionary origin.  The evolutionary conserva- 
tion of/3t is emphasized by the homology (82-86%) main- 
mined between/$~s from widely diverging species, such as 
human, chicken, and frog (9), and 45 % homology between 
human  /3,  and  a  /31-like structure  from Drosophila (36). 
Also, complete sequencing of several integrin ot subunits- 
including those from a fibronectin receptor (or  5) (2,  11), the 
vitronectin receptor (58), platelet gplIb/IIIa (11, 45), Mac-1 
(3,  8,  46),  p150,95  (7),  and  the Drosophila PS2  antigen 
(6)-have  revealed  20-60%  similarity  between  any  pair. 
Some of these integrin structures  are receptors for ligands 
containing  the  amino  acid  signal  sequence  Arg-Gly-Asp 
(RGD) or a closely related sequence (49).  Although NH2- 
terminal amino acid sequencing has suggested ,o40% shared 
residues among six different VLA ot subunits (24, 60), com- 
plete sequence information is available for only one VLA ot 
subunit  (or  5) (2,  11). Thus,  to further  establish patterns  of 
similarity and differences among VLA/integrin sequences and 
to gain basic information for future studies of structure, func- 
tion, and regulation,  the complete sequence of the VLA ot  2 
subunit  was obtained.  Also,  because the ot2-subunit  NH2- 
terminal sequence predicted from cDNA did not match the 
previously published  "or  2" NH2-terminal  sequence,  experi- 
ments were carried out to resolve this discrepancy. 
Materials and Methods 
Purification of VLA-2  from Platelets and 
NHz-terminal Sequencing 
VLA-2 protein was purified from outdated platelets (from the Dana-Farber 
Cancer Institute [Boston, MA] blood bank or from the American Red Cross 
[Dedham,  MAD  by  lectin-Sepharose and then  by  12FI  or  A-1A5 im- 
munoaffinity  chromatography  (60).  The anti-~  2 mAb 12F1 (43) and the 
anti-~ mAb A-IA5 (18) were obtained as described. For NH2-terminal 
amino acid mierosequencing of the 62 subunit, the ~2 subunit was first 
separated  from the/ff subunit by SDS-gel electrophoresis,  transferred to a 
polyvinylidene difluoride  membrane (Immobilon; Millipore Continental 
Water Systems, Bedford, MA), stained with Coomassie blue, and destained 
as described (39).  Excised membrane pieces containing 62 material  were 
then sequenced  using a gas-phase sequenator (470A;  Applied Biosystem, 
Inc., Foster City, CA) equipped with a phenylhydantoin amino acid analyzer 
(120A; Harvard Microsequeneing Facility, Cambridge, MA). 
Preparation of aZ-Subunit-specific Antiserum 
Subunits migrating in the o~ position (,050 #g from A-IAS-Sepharose  or 
12FI-Sepharose)  were reduced  and separated  using preparative 5% SDS- 
PAGE, stained with Coomasie blue, and destained in 7 % acetic acid and 
30%  methanol. The band corresponding to a2 peptide was  cut out and 
electroeluted  into Tris/glycine/SDS  buffer using an Elutrap (Schleicher & 
SehueU, Inc., Keene, NH). The eluted peptide was used for rabbit immuni- 
zation as previously  described (23).  Also, 62 protein purified from 12F1- 
Sepharose  was used for immobilization onto CNBr-Sepharose (Pharmacia 
Fine Chemicals, Piseataway, N  J) according to the manufacturer's  instruc- 
tions, except that 0.1% of SDS was included in the coupling buffer. Antibod- 
ies from rabbit anti-a2-subunit antiserum were then purified using the 62- 
Sepharose affinity column. Briefly, the antiserum was passed through the 
column several  times and the column was  washed successively  with 3 
column volumes each of PBST (0.14 M NaCI,  10 mM sodium phosphate, 
0.2% Tween 20), 0.2 M KSCN,  and then PBST again.  For elution of 62- 
subunit-specific IgG, 3 M KSCN was added, and the eluate was desalted 
by Sephadex G-25 chromatography  into PBST in the presence of 0.1% he- 
moglobin as carrier.  Immunopurified IgG was further incubated with dena- 
tured Escherichia coil protein coupled to Sepharose, and with glycoprote,  ins 
from Molt-4 cells coupled to Sepharose to remove additional  nonspecific 
reactivity. The Molt-4 leukemic T cell line does not usually express VLA-2 
(22). 
Production of  Antibodies to an ~2 COOH-terminal 
Synthetic Peptide 
A 22-mer consisting of the COOH-terminal 21 amino acids predicted  from 
the c~  2 sequence,  with an added cysteine at the NH2-terminal  end of the 
peptide,  was synthesized  by Multiple Peptide Systems  (San Diego,  CA). 
This peptide was coupled to carrier protein (keyhole limpet hemocyanin) 
using m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (Pierce Chemi- 
cal Co., Rockford,  IL) as previously  described (29),  and then rabbit anti- 
bodies were generated using standard  techniques (38). 
Isolation of the Gene Encoding the ~2 Subunit 
A phage ),gill expression eDNA library of human lung fibroblast IMR-90 
(CIontech Laboratories,  Inc., Palo Alto, CA) was screened by using afffinity- 
purified rabbit antibodies against 62 subunit according to Young and Davis 
(67), except that alkaline phosphatase-conjugated anti-rabbit IgG was used 
as a second antibody. Alkaline phosphatase activity was detected by using 
an immunoscreening system (ProtoBlot;  Promega Biotec,  Madison, WI) 
with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as 
substrates.  Positive clones from the screening were plaque purified,  and 
then phage DNAs were purified by the plate lysate method (37). After the 
insert was excised from the phage by Eco RI restriction enzyme digestion, 
the inserts were separated On agarose gels, electroeluted,  and subcloned into 
pBluescript  plasmid (Stratagene,  La Jolla, CA). A eDNA library made in 
kgtll  from endothelial cells was the kind gift from Dr.  Tucker  Collins 
(Brigham and Women's Hospital,  Boston,  MA). 
DNA Sequencing 
The DNA sequences  were determined by the dideoxynucleotide  chain-ter- 
mination method of Sanger et al. (50) using adenosine 35S-5'-[ct-thio]tri- 
phosphate. To facilitate complete sequencing of both eDNA strands, a series 
of overlapping  deletion clones were made in both directions as described 
(25) by using the Erase-a-base system (Promega Biotec). 
Other Techniques 
Southern blot analysis was carried out as described (37). For Northern blot 
analysis, 5 #g of each RNA sample was eleetrophoretically  separated on 1% 
agarose gels in buffer containing formaldehyde,  transferred to nylon mem- 
brane (Nytran; Schleieher & Schuell)  (37), and then probed with a nick- 
translated 5.4-kb 62-subunit cDNA (in pBluescript) using standard hybrid- 
ization techniques (37). Western blotting (63) and immunoprecipitation  (22) 
were performed as previously  described. 
Results and Discussion 
Cloning of  cDNA with a2-Subunit-specific Antibody 
as Probe 
Affinity-purified rabbit anti-c~ ~ antiserum was tested by im- 
munoblotting  of whole  platelet  lysate  and  found  to  bind 
specifically to platelet VLA a s subunit (Fig.  1), thus affirm- 
ing the suitability  of the serum for library  screening.  The 
affinity-purified  antibody was then used for immunoselection 
of clones from a phage Xgtll expression eDNA library made 
from human lung fibroblast (IMR-90) since fibroblasts  were 
known to be good source for ~2 protein (21). After subclon- 
ing into plasmid, a representative  positive clone (clone 2.38, 
,,ol.2 kb) was directly sequenced and found to have partial 
homology to known sequences of other ot subunits in the inte- 
grin superfamily. Subsequently,  clone 2.38 was used to probe 
a human endothelial cell ~,gtll library (another good source 
for ot  2 expression) since that library had longer inserts. Thus, 
another clone was selected (clone 2.72, ,,o5.4 kb), completely 
sequenced, and found to include all of the coding region and 
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relation  to  the  two  distinct  NH2-terminal  sequences  de- 
scribed here. 
Figure 1.  Immunoblotting analy- 
sis of rabbit antibody after en- 
richment for ~  specificity.  After 
SDS-PAGE separation of purified 
platelet VLA proteins, the pro- 
teins were blotted onto nitrocellu- 
lose and then incubated with rab- 
bit  anti-/3~ (lane a)  or  anti-~ 
purified (see Materials and Meth- 
ods)  rabbit antiserum (lane b). 
Bound primary antibody was lo- 
cated using ~2SI-labeled  goat anti- 
rabbit second antibody. 
some of the 3' and 5' untranslated regions (Fig. 2).  Notably, 
the sequence of clone 2.38  (from a  fibroblast library) was 
identical to the corresponding region in clone 2.72  (from an 
endothelial cell library). 
Comparison of Clone 2.72 cDNA Sequence with ~z. 
Subunit NHrterminal Protein Sequence 
Surprisingly,  the previously published 03 NH2-terminal  se- 
quence FNLDTEXDNVFRGP (Fig. 3 A) only partly resem- 
bled the 03  NH2-terminal  sequence YNVGLPEAKIFSGPS 
encoded by eDNA (Fig. 3 C), with homology in only 5 of the 
14  positions.  To resolve this discrepancy,  additional NH2- 
terminal amino acid sequencing was carded out. Using mAb 
12F1-Sepharose,  VLA-2 material was  purified either from 
platelets  or placenta.  After preparative  SDS-PAGE,  highly 
purified 03 subunit from either source yielded an NH2-termi- 
hal amino acid sequence of YNVGLPEAKIFSGPS (Fig.  3 
D), identical to the sequence encoded from eDNA (Fig. 3 C). 
In another experiment, VLA proteins were purified from 25 g 
of platelets using the anti-/3  mAb A-IA5, and the resulting 
mixture of subunits was then separated by reducing SDS-PAGE 
so that ~x  5 and ol  6 subunits would migrate at  130,000 M,, 
away from the 160,000-M, oF subunit (23).  Upon NH2-ter- 
minal amino acid sequencing of the purified B~-associated 
160,000-M~ 03-like protein from the reduced gel, a mixture 
of the YNVGLPEAKIFS and FNLTDXEDNVFR sequences 
was present, with approximately equivalent molar ratios (Fig. 
3 B). Thus, it appears that the latter sequence may belong 
to a protein of 160,000 Mr that is distinct from 03, though it 
closely resembles  oe  2 in  size.  At present,  nothing else  is 
known  about  this  potentially new  subunit,  other  than  it 
appears  to coprecipitate with  /3l  (when using the anti-Bt 
mAb A-1AS). Because the mAb 12F1 (originally used to de- 
fine VLA-2 [43])  was used to isolate the protein with the 
YNVGLPEAKIFS... sequence, that protein merits the desig- 
nation as the authentic o~  2.  It remains to be seen if the re- 
Northern Blotting Analysis 
The distribution of mRNA for the a 2 subunit was studied 
by Northern blotting with eDNA clone 2.72 as the probe. A 
single  band  at  '~8  kb  was  detected  in  fibroblast  RNA, 
whereas little or no signal at the same position was obtained 
in HSB or Molt-4 T cell lines (Fig. 4). These results are con- 
sistent with the known cell surface expression of VLA-2 on 
these cells (21, 22).  Hybridization of the same blot with a 
cDNA probe for the human actin gene gave comparable sig- 
nals in all lanes. Since the RNA size (8 kb) was somewhat 
larger than the eDNA clone (5.4 kb) and since no poly A tail 
is present (Fig. 2), it is assumed that the 3' untranslated re- 
gion (and perhaps also the 5' end) is incomplete. 
Authenticity of the ~2 Clone 
Despite the unexpected NH:-terminal sequence results, the 
03 clone obtained is authentic because (a) the eDNA was 
selected using antibodies specific for the 03 subunit; (b) the 
NH2  terminus of the predicted  sequence  was  identical to 
that directly determined from purified 03-subunit  protein; 
(c)  the mRNA distribution agrees with that of the mature 
protein; (d) the size of the predicted protein closely agrees 
with the experimental value (see below); (e) the predicted se- 
quence has several features characteristic of other integrin tx 
subunits  (see below);  and  (f)  native 03  protein  could be 
readily immunoprecipitated by antisera prepared against a 
synthetic COOH-terminal peptide including 21 amino acids 
deduced from the 03 cDNA sequence (Fig. 5). 
As shown in Fig. 5 A, rabbit serum directed against an 03 
COOH-terminal synthetic peptide (predicted from cDNA se- 
quence) recognized an oeB complex (lane c) from the colon 
carcinoma cell line CCL-228 that closely resembled VLA-2 
(lane b). Prior removal of all material seen by the rabbit se- 
rum (lane  f) resulted in the simultaneous removal of VLA-2 
(lane e), but only partially diminished total VLA as seen by 
mAb A-1A5 (cf. lanes a  and d).  Also, anti-03 COOH-ter- 
minal peptide sera specifically immunoblotted tx  2 purified 
from platelets using either the mAb A-1A5 (Fig. 5 B, lane a) 
or 12F1 (lane b).  In comparison, serum from a rabbit im- 
munized with isolated tx  2 protein (before anti-03 antibodies 
were purified) recognized mostly a 2 (but also fl~) in prepa- 
rations obtained from platelets using A-IA5 (lane c) or 12FI 
(lane d), whereas a negative control serum did not blot any 
detectable purified platelet protein (lanes e and f). 
Amino Acid Sequence of the ~2 Subunit 
Translation of the eDNA  sequence of clone 2.72  (Fig.  2) 
yielded coding sequences of 3,543 bp (encoding 1,181 amino 
acids) between the 3' and 5' untranslated portions of ~50 bp 
and 1,800 bp, respectively. Preceding the NH~-terminal se- 
quence of the mature protein (YNVGLPE...) is a transla- 
tional start site (30) that codes for a methionine followed by 
29 amino acids, fulfilling the requirements for a signal pep- 
tide (64). Thus, the open reading frame shown in Fig. 2 en- 
codes a mature protein of 1,152 amino acids predicted to be 
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~gure 2.  Complete nucleotide sequence of an ~2-subunit  eDNA clone and d~uced amino acid sequence. The d~uc~  NH2-~in~ 
~ino  acid sequence (YNVGL...),  which mamhes ~e NH2-~inal  ~ino  acid sequence from purifi~ ~2 pro~in, is underlin~; the 
probable transmembrane domain is also underlined. ~e  191-~ino acid I-domain, which is not ~und in o~er ~, or ~3 integrins,  is con- 
mined in ~e la~e box. Thr~ ~tential divalent cation-binding domains am indicat~ ~  small boxes, and ~ssible ~gl~osylation sites 
are marked with asmrisks. Residue  No.:  l  2  3  4  5  6  7  8  9  10  11  12  13  14  15 
B  2  +a~  s?QL)  L/¥  D/G]  t  P  E  II)/A N/l< [IV 
c  ~(~o~)  i Y  .  v  c  t  P  E  A  K  ~  F  S  G  ~1 
D  QZ  (protein)  [  Y  N  V  G  L  P  E  A  K  I  F  S  G  P  S  J 
Figure 3.  Comparison of VLA  ct  2 and  other  NH2-terminal  se- 
quences.  (,4) The NH2-terminal sequence of platelet material pre- 
viously purified using A-1A5-Sepharose and erroneously published 
as the 0/2 sequence (60);  (B) the NH2-terminal sequence from an- 
other preparation of platelet material comigrating with 0/2 on SDS- 
PAGE after A-1A5-Sepharose purification of VLA proteins; (C) the 
0/~- NH2-terminal sequence deduced  from cDNA;  and (D) the 0/2 
NH2-terminal sequence obtained after purification of VLA t~  2 (from 
placenta or platelets) using the mAb 12Fl (which is specific for 0/2). 
126,000  Mr.  The  addition  of 10  potential  N-glycosylation 
sequences (Asn-Xaa-Ser/Thr, average 2,500 Mr) to the core 
protein  would  result  in  an  estimated  molecular  mass  of 
151,000  D.  That value  is close to  the  155,000-160,000  Mr 
estimated  from  u2-subunit  migration  on  SDS-polyacryl- 
amide gels. 
Analysis of the NH2-terminal portion of the sequence re- 
vealed the presence of seven homologous repeating domains 
(Fig. 6). These domains contain 28-41 amino acids and are 
20-30%  similar  to  each  other.  Also,  these  domains  are 
spaced 23-32 amino acids apart, except that there is a large 
additionally inserted "I-domain" of 191 amino acids (see be- 
low) between repeating domains II and III. 
Figure  4. RNA hybridization anal- 
ysis. Total RNA (5 #g/lane)  from 
the  leukemic  cell  lines  Molt-4 
and HSB and from the fibroblast 
cell line MRC was electrophoreti- 
cally  separated  on  1%  agarose- 
formaldehyde gels, transferred to 
nitrocellulose  filters, and probed 
with  full-length  a 2 cDNA.  In a 
control  experiment  (lower pan- 
el), the same RNA samples were 
probed  with actin cDNA. 
The  repeated domains  V,  VI,  and  VII each contain  se- 
quences  of Dx(D/N)xD(G)xxD  (Fig.  2,  small boxes,  and 
Fig. 6, underline) that are somewhat similar to the EF-hand 
consensus metal-binding domains of a  number of calcium- 
and magnesium-binding proteins, including calmodulin, tro- 
ponin C,  parvalbumin (59),  thrombospondin (34),  myosin 
light chain (47),  and galactose-binding protein (65).  These 
potential divalent cation-binding sites in u ~ are located in a 
region (between amino acids 470 and 627) devoid of cysteine 
residues and N-glycosylation sites. The presence of divalent 
cation-binding  sites  in  the  a 2 subunit  is  consistent  with 
divalent cation requirements for the function of VLA-2 as a 
human collagen receptor (51, 52). 
Comparison of  &-Subunit Sequence with 
Other lntegrin ~ Chains 
The alignment of the o?-subunit sequence with the u-chain 
sequences of human fibronectin receptor (VLA-5), vitronec- 
tin receptor, gplIb/IIIa, Mac-l, and p150,95 shows that sev- 
eral structural characteristics are shared (Fig. 7). For exam- 
ple,  of the 20 u2-cysteine residues,  17 are conserved in at 
least three of the other sequences and  14 are conserved in 
all six u-subunit sequences. Also, there is 32-45 % conserva- 
tion in the 22-amino acid transmembrane region and 100% 
conservation of the  GFFKR sequence  on  the  cytoplasmic 
side of transmembrane domain. Additional striking similari- 
ties are evident in the region of the a 2 homologous repeats 
in the NH2-terminal half of the molecule. Like a 2, each of 
the other  integrin  u  subunits  has  also been noted to have 
seven homologous repeats, with three or four potential diva- 
lent cation sites within repeats IV-VII (2, 3, 7, 8,  11, 45, 46, 
58).  In these repeat regions, the average similarity between 
u 2 and the other u  subunits  ranged from 30-38%  (repeats 
I, II, III, and VII) to 46-52 % (repeats IV, V, and VI). The 
overall similarity between u 2 and the other integrin a  sub- 
units is 18-25%, or 22-24%  if the 1-domain (see below) is 
excluded. This is in contrast to the higher degree of identity 
(~45%) between different human integrin fl chains (2,  12, 
28,  33,  62). 
Comparison of the a2-Subunit 1-Domain 
with Similar Domains in Other Proteins 
In studies of Mac-1 (3, 8, 46), p150,95 (7), and LFA-I (32), 
an inserted domain of '~200 amino acids was found that is 
not present in the u 5, u v, or IIb chains. In those studies, the 
inserted I-domain (32) (formerly called the L-domain) was 
noted  to  resemble the  von Willebrand  factor  (vWF)'  AI, 
A2, and A3 domains, cartilage matrix protein (CMP)-t and 
CMP-2 domains, and domains in complement factors B and 
C2. Now an I-domain has also been discovered in the u 2 se- 
quence.  The  sequence  of the  c~  2 1-domain  is  aligned  with 
other related domains as shown in Fig. 8, and percent simi- 
larity calculations from those data were used in the construc- 
tion  of the  linkage tree  shown  in Fig.  9.  The u 2 1-domain 
sequence (allowing for conservative amino acid substitutions) 
most  resembled  I-domains  from  p150  (48%)  and  Mac-I 
(45%)  and  also  resembled the  CMP-1  (46%)  and  CMP-2 
(44 %) domains. Less similarity was seen with vWF domains 
1. Abbreviations used in this paper:  CME  cartilage  matrix protein;  vWF, 
yon Willebrand  factor. 
Takada  and Hemler Primary Structure of VLA-2 ct Subunit  401 Residue Ho.: 
I  EQFGYAVQQFINPKGN  .... WLLVGSPWSGFPENRM---GDVY  17-52 
II  I  III 
II  MSLGLILTRNMGTGG  ..... FLTCGPLWAQQCGNQYYTTGVCS  84-]18 
II  I  III 
Ill  SQVGFSADYSSQ  ...... NDILMLGAVGAF .........  GWSG  350-377 
l  lili  I  II  I 
IV  SYLGYSVMIST--GES---HFVAGAPRANYT  ....... GQIV  405-437 
lli  I  I  i  IIII  i  I 
V  SYFGSVLCSV-DVDKDTITDVLLVGAP--MYMSDLKKEVGRVY 460-499 
i  lli  I  I  il  I  llil  I  i  II 
VI  TRFGSAIAALSDINMDGFNDVIV-GSPL  .... ENQNNS-GAVY  523-559 
II  ]  lii  I  II  i  I  I  I 
VII  QYFGRSLDGYGDLNGDSITDVSI-GAFGQVV-QLWSQSIADVA  587-627 
Putative ~2  divalent  N 
cation  site:  DxDxDGxxD 
Consensus divalent  DxDxDGxxDxxE 
cation  site  from 
the  literature  (59) 
Figure 6. Alignment of seven homologous repeated domains in the 
a2 subunit.  Residues that are the same in adjacent sequences (in- 
cluding conservative  subsitutions)  are marked  with ve~ical con- 
necting lines. Conservative substitutions are I, V, L; Y, W, F; A, 
G; S, T; R, K; D, E; N, Q. 
Figure 5.  Recognition  of ~2 protein  by rabbit  serum  against  t~  2 
COOH-terminal synthetic peptide. (A) Immunoprecipitation of VLA 
proteins from tzSI-radiolabeled  CCL-228 cells (a colon carcinoma 
line) was carried out using the mAb AolA5 (lanes a and d),  12FI 
(lanes b and e), and rabbit anti-t~  2 COOH-terminal  peptide (RS, 
lanes c and f) either with (lanes d-f) or without (lanes a-c) prior 
immunodepletion  of all rabbit serum-reactive material.  (B) The 
A1 (32%), A2 (36%), and A3 (37%), and with complement 
factors B  (29%) and C2  (26%). 
The vWF protein contains at least two independent colla- 
gen-binding sites, localized to the A1  and A3 domains (42, 
48) and, likewise, CMP-1  and CMP-2 domains may be used 
to  mediate  interaction  with  collagen  (1). Because  VLA-2, 
vWE and CMP all  share related domains and can interact 
with collagen, that suggests the I-domain may be important 
for adhesion to collagen. However, the presence of an 1-do- 
main  (or  related  sequence)  does  not  completely correlate 
with a collagen adhesion function since there is no evidence 
that p150,95 or Mac-1  interact with collagen and, likewise, 
complement factors B  and C2  are not known to bind col- 
lagen. 
Grouping of lntegrin ~ Subunits into Subsets 
From sequence analysis, together with earlier data, it is clear 
that there are several structural features that distinguish inte- 
grin ct subunits containing I-domains from those that do not 
(Table I). It has previously been noted that the mature forms 
of integrin c~ subunits t~  s, a v, and lib each contain a cleaved 
peptide fragment (the COOH-terminal  15 % of the protein) 
that is attached to the rest of the subunit by a disulfide link- 
age. Consistent with this, dibasic protease cleavage sites have 
been noted in the appropriate locations in each of those se- 
quences  (2,  35,  58).  Notably  (Table I),  the  subunits  with 
I-domains (~2, c~M, and p150) do not undergo protease cleav- 
age, whereas the cleaved subunits do not have I-domains. In 
this regard, in the region where protease cleavage occurs for 
t~5, ~v, and lib, the three I-domain subunits have gaps of 20 
or more amino acids and no dibasic amino acids (see Fig. 
7,  a 2 position  1,018). 
mAbs 12FI and A-1A5 were used to purify either VLA-2 or total 
VLA protein from platelets (see Materials and Methods). Then ali- 
quots of purified proteins  were separated by SDS-PAGE, blotted 
onto nitrocellulose, and probed as described (63) using rabbit anti- 
intact ot  2 plus B~ (lanes a  and b), anti-COOH-terminal synthetic 
peptide (lanes c and d), or control  rabbit serum (lanes e and f). 
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VLA2  ~-'~F  I F  S  L  K~'I'  - TF~s  V  RV-S~P~TV I~  I~T  EFE~I~  -Fv"Q'T'~ K  .....  :AE~--L'K-~G  Q  T~  S  S  VF~F~  S  E  N  F  R  1014 
VLA5  IP~VHHVYE L I N~P  S S~Q~VLE nS dP~-AL~GQ~I~R~VRT~--A~-  L~TT-~H  ~I NRKG  n'E LDP E GA~LHHQQ--  851 
IIB  ~VV  ~  S~G~  S~  ~I~-LD~'PQ  ~  ~  ~iNNpP~  P~  852  EHTYELHN  P°  NGLHL  G-QSQPS  I-L°  PQG  -L  Fp-Qpp NPL  DWG  LP  I  PSPIHPA 
VNR  QHIYELRN  PS  LHLQ  KYN  HYDI~-  PM  TS--DM  KI S~LQTTE~NDTVA  848 
Macl  -VMQHQYQ~S  N~QRS LP-  I  S  LVF  L~VRLNQTVIWDRPQVTF S  E  N-  LS-  S~HTKER-  L~P~H'~-  S  DF  LAELR~A ....  1002 
plS0  -VAMHRYQ~NNL~QR  D  LP-V  S  I  NFW~VELNQEAV~DVEVSH  PQN-  p  S-  LR~S  S-E  K-~A~PA-  S  DF  LAH  I  Q-~N  ....  998 
wA2  ~g  ....................  -Fq~,~s--~s~,F~~Y~N~---~~ss,~,~--~  lO~ 
VLA5 -~R  .......  EAPSRSSASSGPQ  I-L~P~E-~FRL~O~GP~L~QQESQSLQLH---~%T~A  T~LQRE~PFS-~  914 
IIB  ~RDRRQIFLPEPEQPSRLQDPVLLV~D~P-~qTV~Q£MARGQRAM~T~---LAF~LPSLYQR---pL~F~  925 
VNR  GQG-~RDHL--  I T KRDLALS  E° DIHT~G~Q-~LK  I~Q~GRLDR° KSAI LY~K--- S LI~TE~MNKE N~NH SYS~  920 
~a¢1  ......................  ~v--~<~s  ~v--tqQs~qo~  VFFG~0~F~F~AT,.KGNLSF~  KTSHHHLLI ....  V  1052 
pl50  ......................  pV--L~I~s  I~G--~LRFI~DVP  S  FSVQI~LDFT  LKGN  LSWG~'VRQ  I  LQ  KKVSV  ....  V  1048 
v~2  ~A~yn--~  ~  .....  -i~Y~  --  D~  li~,~  ~  -R~EVT~-~F~-~L~.wz  ~W~L°  F  F  ~K -~  ii~ 
VLA5 Q  C  E~VY  KAL  KMP Y  R  I I~RRQ  L  P  Q  KE  R  -QV~'I~AVQWT  KAE  G  S  YG--~  I~LWT~.~L.~LG F  I~L  L  I~G  I~L~-~I  L~KLG  F  F  KRS L~  991 
IIB  Q  S ~gF~V  S S L P YAV ~LS  LP ROE A-QV~Q L~RAL--  E~R~--~I~VGV  LG~LL~T~L~---M~E~G F F K~NR  p p  1000 
VNR  KS  ~  SA~V I  E  F  PYKN~E  E~Y--NS~LVTTNVTWG  I  Q  PAPMP~LAVL~LLL~L~FVM~-~GF  FK~VRP  p  997 
Mac1  S-~AE~FLFNDSVFT LI~I~-GQGAFVRS~EF~KVEP F E ....  V  P  N  P~R-  L-i~  S~V  -~d L  L  IIA  L  I'~-T~A~Y~LO  F  F  K  ~Q  -  -~  1022 
plS0  S--VLA_~TF  °T  SVX  S  Q  I~-°Q  EAFMRA~TL_~vL£ KyK  ....  VHNPTL~-  L  I  VG  SS~-  GL~ L  LIt~_~L I  TL~X~.~KF~G  F  F  KI~Q  --~  1118 
VLA2  E  ~TKNP~I  DETT~LS~  1152 
°,.As o~A~-~K~0,~K--~  ~A~aDA  i  008 
~  '  ....  ~G~  ~009 
VNR  Q  ....  EEQ~REQLQPHENGEGNSET  1018 
Mac1  K~M-SEGGPPGAEPQ  1137 
pl50  KE~M-EEANGQ  IAP~NGTQTPSPPS  EK  1144 
Figure Z  Alignment of the (x-chain protein sequences of VLA-2 with other integrin (x subunits. The (x2 sequence is compared to human 
integrin (x-subunit sequences from fibronectin receptor (2,  11),  gpIIb (45),  vitronectin receptor (58),  Mac-l  (3,  8),  and p150 (7).  The 
19 l-amino acid I-domain present in (x2 (residues 159-349),  as well as corresponding regions in p150 and Mac-l, have been omitted from 
this figure (see Fig.  2).  Residues in other sequences identical to those in (x2 are boxed.  In four places,  short gaps appear in all six se- 
quences.  These gaps allow for maximized future alignment with VLA a * sequence (61a). a :t p h a 2  I'd"~Q z -[UV-vlvl~Jc~p.t~t,,~'d~- - ul~~~-I~]'r  -I'Kl'~-IO  v  G  L  z..q.Y  A~v~i-~,  z 
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v  ~ F  A 2  R L - P  G -  - -~  .......  {I[0  V V FII~{V]-IG~P  -~-~N  V Q -  EI4R  R -II~-  G U PPN  ~PI  .....  I L  -~I Q D F  F.  .......  IT]  ....  ~- L P  R 
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c2  RILNZm0K .....  a N D r L D I Y  Ai~M-IGI- - - R L D  VIeW  R ~tqN-~L - - - GISlKK  D  ~.q.L~IH AI..~II L- - - 0 DT ~ A ......  LLIH -101VI~R 
alpha2--~-~-~-~V~O  N--~-~H~'ffS-~  140-351 
CMPI  V -II~K  l-~JH  g LT  H  KG-IF  ~P.  A F  C  V  1-143 
C.F2  ~-~SNZ~L0.~  .........  ~9~-3r0 
Hac-I  -  -II'~-IG'~-[~T['~S S S ~E  ~  1Z8-336 
p15O  --ILP.I-GIE_~.IP.  T T S S S S-Irle L-IMIAIOI  126-334 
v~/F  A1  P--IEI-APEAPPPTLPPD--IHIAIOJ  509-712 
,,~F  ~2  -M-~-~L-DAV  ....  ~ac-el~  73Z-909 
vgF  A3  -H----VITILj~NSF--LIIKLC#~G  923-1111 
B  O HIIID  E - S  -lOIS  L S  - -  -  L-  C  C4_~V  g  241-457 
C2  BHLD-VSK--  LTDT-  I-CGVGN  230-447 
Figure 8.  Comparison of the c~  2 I-domain with similar domains in other proteins. CMP-I  and CMP-2 domains (1),  I-domains from the 
subunits of Mac-1 and p150,95  (3, 7,  8),  vWF domains A1,  A2, and A3 (54), and domains in complement factors B  (40) and C2 (4) 
are compared to the I-domain from a 2 (amino acid residues 140-349). Although the actual inserted I-domain sequence in c~  2 is 191 amino 
acids (residues 159-349), additional c~  2 amino acids (residues 140-158 and 350-351) are included to accommodate similarities with other 
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Another feature that differentiates between these sets of ct 
subunits is the number of potential divalent cation sites. The 
cleaved subunits have four such sites (located in repeat re- 
gions IV,  V,  VI,  and VII),  whereas  the I-domain  subunits 
have only three sites (located  in repeats V,  VI,  and VII). 
Not only are there differences in the number of divalent 
cation sites, but evidence also suggests that the two groups 
of integrin a  subunits may each have their own characteristic 
intrachain disulfide loops.  Analysis of cysteines (Fig.  7) re- 
veals that the majority (14 cysteines) are conserved through- 
out all six integrin ct-subunit sequences.  However (Table I), 
Figure 9.  Linkages between cG-subunit I-domains and similar do- 
mains in other proteins. Based on the alignment in Fig.  8, percent 
similarities were calculated (allowing for conserved amino acids as 
defined in Fig. 6), and then linkage trees were determined by stan- 
dard procedures using the average linkage values (55). Similar de- 
terminations, not allowing for conserved amino acids  (based on 
percent identical amino acids only), yielded similar results except 
that ct  2 clustered with CMP-1 and CMP-2 instead of a M and p150. 
The Journal of Cell Biology, Volume  109,  1989  404 Table L Structural Features Distinguishing 
Integrin ot Subunits with l-Domains from ce Subunits 
That Are Cleaved 
Divalcnt 
lntegrin  Protease  cation 
a  subunit  I-Domain  cleaved  sites 
Residues at u2 positions 
110  467  350  645 
ct  2  Yes  No  3  Cystl0  Cyst7  Ser3s0  -645 
a M  Yes  No  3  Cys97  Cys~  Ser33~  GIy53, 
p150  Yes  No  3  Cys97  Cys.4  Ala333 Vals31 
c:  NO  Yes  4  Lysl25  Ala289 Cyst64  Cys4sl 
IIb  No  Yes  4  Glu117 Ala295 Cysi67  Cys484 
c~  v  No  Yes  4  MetN2  Ala2go Cysts5  Cys472 
PS20t  No  Yes  4  Thrj57  Ala337 CysI9s  Cys53t, 
cysteines  at positions  110  and  467  in  the  ot  2 sequence  are 
conserved only among et  2, a M, and p150.  Conversely, at ot  2 
positions  350  and  645,  cysteines  are  absent  from u2,  etM, 
and p150, but present in all of the cleaved subunits.  Thus,  it 
might be predicted that each group of subunits  (cleaved or 
with I-domains) may have a characteristic  intrachain  disul- 
fide loop that distinguishes  one group  from the other.  Al- 
though the newly derived sequence for the c~  L chain of LFA- 
I (32) is not shown here, that sequence has an I-domain and 
fits the pattern shown in Table I with respect to potential diva- 
lent cation sites and conserved cysteine residues.  Structural 
information for the Drosophila PS2 ct subunit (6) is also in- 
cluded in Table I. Although the source is phylogenically far 
removed from humans,  the properties of that ct subunit are 
fully consistent  with  the properties  of the other cleaved ot 
subunits. 
In addition to the "group-specific" cysteine residues men- 
tioned in Table I, there are many other amino acids at posi- 
Table II. Comparison of Subsets of or Subunits  That Show 
Amino Acid Identity  at the Most Positions" 
Subset of  Positions  Common 
ct subunits  with identity  (No.)  features 
Part A 
Part B 
~5,  lib,  t~  v  99  Cleaved subunits 
od, p150,  uM  64  1-Domain 
c:, tx  2, a v  24  - 
lib, o~  M, pl50  21  - 
~5, p150, ot  M  19  - 
av, ~M, plS0  19  - 
cd,  c:, IIb  13  - 
~2, lib, ct  v  13  - 
p150,  o?  ~  256  f12 
o:,  t~  v  109  - 
Ilia, o~  v  65  /33 
a s, lib  62  - 
t~  2, Ilb  40  - 
ct  2, c~  v  35  - 
cd,  ~  31  fll 
* Sets  of  sequences,  shown  in  order  of  prevalence,  were  derived  from 
computer-generated lists of positions in which only three (part A) or only two 
(part B) identical amino acids are shared. Sequence information from 1-do- 
mains (residues 159-349 in a 2) was omitted for these determinations. 
tions throughout the aligned sequences that distinguish I-do- 
main  integrins  from  cleaved  integrins.  In  fact,  when  the 
aligned sequences (Fig. 7) were searched by computer to find 
all positions in which exactly three sequences had identical 
amino acids, this was found to occur most often (at 99 posi- 
tions) among the set o:, IIb, and ctv and also occurred often 
(at 64 positions) among the set cd,  p150,  and ot  u  (Table II, 
part A). Thus, the I-domain subunits could again be distin- 
guished from the cleaved subunits, this time based on exclu- 
sively shared amino acids distributed throughout the coding 
region. Other sets of three subunits shared amino acids less 
frequently (at ~< 24 positions) and had no obvious structural 
similarities.  Thus the results from the data in Table II, part 
A,  support the conclusions  drawn  from Table I. 
Because  the  u 2 and  o:  subunits  both  associate  with  the 
same fl subunit (fl,), it might be assumed that these two se- 
quences would show exclusive amino acid identity at several 
positions. However, when a computer search was performed 
(Table II, part B),  positions  with  amino  acid  identity  be- 
tween only c~  2 and  c: were  not very prevalent (seventh  in 
the  list  of subunit  pairs).  In  fact,  ct 2 was  more  likely  to 
share residues with lib or av than with 0:, and a 5 was more 
likely to share residues  with o~  v or lib than with od.  Thus, 
despite their common fl-subunit association,  the ot  2 and a 5 
subunits  have relatively  few amino  acids  common  to only 
those sequences, making it difficult to predict potential o~-sub- 
unit  sites that may be specific for fit interaction. 
Summary 
Cloning and sequencing of the ct  2 subunit of VLA-2 has re- 
vealed  its  complete  primary  structure,  and  confirmed  its 
relatedness to other integrin c~ subunits.  The presence of an 
ct  2 I-domain,  which  possibly  participates  in  VLA-2 adhe- 
sion to collagen has been established, and comparative stud- 
ies of the cd sequence have revealed that subunits containing 
I-domains  have a  number  of additional  structural  features 
that distinguish them from cleaved integrin t~ subunits.  Also, 
it is clear that fl-subunit use does not accurately predict the 
relative degree of similarity between integrin c~ subunits. For 
future studies, the results shown here will provide the basic 
information  and  materials  needed  for (a) additional  struc- 
tural comparisons with other integrins; (b) analysis of VLA-2 
function through expression and mutagenesis; and (c) analy- 
sis of patient  samples to measure deficient or mutated ct z. 
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